1006 completed. 1006 Phase 2, 221 Phase 1, 28 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1006 | Completed 1006 |
| Phase 1 | 221 | Completed 221 |
| Phase 3 | 28 | Completed 28 |
Follow Bone Marrow Diseases: new trials by email Literature Review of Bone Marrow Diseases trials Research Report on Bone Marrow Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of HSK39297 in Patients With Paroxysmal Nocturnal Hemoglobinuria（PNH） HSK39297 - Paroxysmal Nocturnal Hemoglobinuria (PNH) | Phase 2 | Completed | Haisco Pharmaceutical Group Co., Ltd. | 47 | 2024-07-17 | 2025-06-29 |
| Ustekinumab for Intestinal Behçet's Syndrome With Myelodysplastic Syndrome Ustekinumab 90 mg - Behcet's Syndrome, Intestinal Type, Myelodysplastic Syndrome | Phase 2 | Completed | Liu Tian | 8 | 2024-03-24 | 2026-05-13 |
| Proof of Concept Study to Assess the Efficacy, Safety of HRS-5965 in Patients With Paroxysmal Nocturnal Hemoglobinuria HRS-5965 tablets - Paroxysmal Nocturnal Hemoglobinuria | Phase 2 | Completed | Chengdu Suncadia Medicine Co., Ltd. | 26 | 2023-11-15 | 2024-10-15 |
| A Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Polycythemia Vera (IMG-7289-CTP-203/MK-3543-004) Bomedemstat - Polycythemia Vera | Phase 2 | Completed | Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) | 20 | 2023-09-07 | 2026-05-07 |
| Venetoclax After TKI to Target Persisting Stem Cells in CML Venetoclax - Chronic Myeloid Leukemia | Phase 2 | Completed | Thomas Ernst, PD Dr. med. | 10 | 2023-08-31 | 2026-08-18 |
| Study of the Selective GlyT1 Inhibitor Bitopertin for Steroid-Refractory Diamond-Blackfan Anemia Bitopertin - Steroid-refractory Diamond-Blackfan Anemia (DBA) | Phase 1 / Phase 2 | Completed | National Heart, Lung, and Blood Institute (NHLBI) | 15 | 2023-07-25 | 2026-06-30 |
| A Study of MY008211A in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) MY008211A tablets - Paroxysmal Nocturnal Hemoglobinuria | Phase 2 | Completed | Wuhan Createrna Science and Technology Co., Ltd | 34 | 2023-07-06 | 2025-07-30 |
| Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy Imetelstat sodium - Myelodysplastic Syndromes, Acute Myeloid Leukemia | Phase 2 | Completed | GCP-Service International West GmbH | 46 | 2023-06-05 | 2026-10-02 |
| Safety and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria Patients With a Sub-optimal Response to Ravulizumab OMS906 - Paroxysmal Nocturnal Hemoglobinuria | Phase 2 | Completed | Omeros Corporation | 12 | 2023-03-27 | 2025-10-01 |
| Efficacy and Safety in Transfusion Independent Non-severe Aplastic Anemia Luspatercept, Cyclosporine - Aplastic Anemia | Phase 2 | Completed | Bing Han | 58 | 2022-12-19 | 2025-09-16 |
| The Use of Eltrombopag Post HSCT in BMFD Eltrombopag 25 MG Oral Tablet, Supportive care - Stem Cell Transplant Complications | Phase 2 / Phase 3 | Completed | The First Affiliated Hospital of Soochow University | 118 | 2022-10-22 | 2025-12-03 |
| Fedratinib in Combination With Nivolumab Fedratinib Oral Capsule [Inrebic], Nivolumab - Primary Myelofibrosis, Secondary Myelofibrosis | Phase 2 | Completed | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 30 | 2022-06-14 | 2026-04-08 |
| Study of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients Azacitidine, Venetoclax, Flumatinib - Philadelphia Chromosome, Acute Myeloid Leukemia | Phase 2 | Completed | The First Affiliated Hospital of Soochow University | 20 | 2022-05-01 | 2024-04-25 |
| Treosulfan-Based Conditioning Regimen Before a Blood or Bone Marrow Transplant for the Treatment of Bone Marrow Failure Diseases (BMT CTN 1904) Treosulfan, Fludarabine Phosphate, Tacrolimus - Bone Marrow Failure Syndrome, Congenital Amegakaryocytic Thrombocytopenia | Phase 2 | Completed | Fred Hutchinson Cancer Center | 40 | 2022-04-19 | 2026-03-09 |
| Off-the-shelf NK Cells + SCT for Myeloid Malignancies Cyclophosphamide, Mesna, Filgrastim - Myeloid Malignancies, Acute Myeloid Leukemia | Phase 2 | Completed | M.D. Anderson Cancer Center | 24 | 2022-04-08 | 2025-12-19 |
| PTCy + Sirolimus/VIC-1911 as GVHD Prophylaxis in Myeloablative PBSC Transplantation VIC- 1911 - Acute Leukemia, Myelodysplastic Syndromes | Phase 1 / Phase 2 | Completed | Masonic Cancer Center, University of Minnesota | 16 | 2022-03-17 | 2025-12-22 |
| Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL) Fedratinib Pill - Myeloproliferative Neoplasm, Chronic Neutrophilic Leukemia | Phase 2 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 25 | 2022-03-01 | 2026-06-09 |
| A Study to Evaluate Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx) in Patients With Polycythemia Vera sapablursen - Phlebotomy Dependent Polycythemia Vera | Phase 2 | Completed | Ionis Pharmaceuticals, Inc. | 50 | 2021-12-30 | 2026-07-09 |
| Safety of Flonoltinib Maleate Tablets for the Treatment of Patients With Myeloproliferative flonoltinib 25mg, flonoltinib 100mg, flonoltinib 150mg - Myeloproliferative Neoplasm (MPN), Myelofibrosis，MF | Phase 1 / Phase 2 | Completed | Chengdu Zenitar Biomedical Technology Co., Ltd | 31 | 2021-12-27 | 2025-10-01 |
| An Extension Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Myeloproliferative Neoplasms (IMG-7289-CTP-202/MK-3543-005) Bomedemstat - Thrombocythemia, Essential, Primary Myelofibrosis | Phase 2 | Completed | Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) | 81 | 2021-12-15 | 2025-09-22 |
Showing 20 of 1006. Sign in to see all of them.
Myelodysplastic Syndromes (493) · Leukemia, Myeloid, Acute (386) · Leukemia (303) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (228) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (221) · Myeloproliferative Disorders (164) · Leukemia, Myelomonocytic, Chronic (150) · Primary Myelofibrosis (148) · Lymphoma, Non-Hodgkin (143) · Leukemia, Myeloid, Chronic-Phase (135) · Leukemia, Lymphocytic, Chronic, B-Cell (132) · Hodgkin Disease (130) · Multiple Myeloma (122) · Blast Crisis (113) · Leukemia, Myeloid, Accelerated Phase (107)
Hemic and Lymphatic Diseases (1006) · Hematologic Diseases (979) · Neoplasms (711) · Neoplasms by Histologic Type (683) · Leukemia, Myeloid (605) · Pathological Conditions, Signs and Symptoms (490) · Pathologic Processes (486) · Disease Attributes (476) · Chronic Disease (460) · Myeloproliferative Disorders (406) · Leukemia (370) · Immune System Diseases (319) · Immunoproliferative Disorders (290) · Lymphatic Diseases (286)
Cyclophosphamide (136) · fludarabine phosphate (125) · Busulfan (100) · Cyclosporine (94) · Mycophenolic Acid (88) · Peripheral Blood Stem Cell Transplantation (83) · Antilymphocyte Serum (82) · Cytarabine (79) · Tacrolimus (74) · Whole-Body Irradiation (73) · Azacitidine (72) · Filgrastim (67) · fludarabine (66) · Imatinib Mesylate (54) · Methotrexate (54)
M.D. Anderson Cancer Center (99) · Fred Hutchinson Cancer Center (69) · National Cancer Institute (NCI) (48) · Novartis Pharmaceuticals (41) · National Heart, Lung, and Blood Institute (NHLBI) (40) · Memorial Sloan Kettering Cancer Center (37) · Masonic Cancer Center, University of Minnesota (20) · Groupe Francophone des Myelodysplasies (16) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (16) · Case Comprehensive Cancer Center (15) · Celgene (15) · Bristol-Myers Squibb (14) · H. Lee Moffitt Cancer Center and Research Institute (14) · Roswell Park Cancer Institute (9) · Weill Medical College of Cornell University (9)
United States (737) · Italy (101) · France (93) · Germany (92) · United Kingdom (77) · Canada (76) · Spain (52) · South Korea (46) · Australia (41) · Belgium (35) · China (34) · Japan (32) · Netherlands (26) · Austria (24) · Sweden (23)
Brenda Sandmaier (12) · Guillermo Garcia-Manero, MD (9) · Jorge Cortes, MD (9) · John Mascarenhas, MD (6) · Neal S Young, M.D. (6) · Ayalew Tefferi, MD (5) · Danielle M Townsley, M.D. (5) · Jorge E Cortes, MD (5) · Judith Karp (5) · Kyoo H. Lee, MD (5)
PMID 32499241, PMID 34724566, PMID 23524640, PMID 23065508, PMID 29674506, PMID 23620574, PMID 25361995, PMID 27658437, PMID 28835440, PMID 29958797, PMID 30885996, PMID 35235189, PMID 17715389, PMID 18997171, PMID 21403127, PMID 22067384, PMID 22133778, PMID 22430088, PMID 24383844, PMID 25527568, PMID 27400247, PMID 28870615, PMID 30992268, PMID 32343796, PMID 35007144, PMID 35998303, PMID 36054756, PMID 40593138, PMID 41758981, PMID 10204198, PMID 1090310, PMID 11054091, PMID 11331327, PMID 11468154, PMID 11585760, PMID 12622583, PMID 12750167, PMID 15339678, PMID 15514371, PMID 15817673, PMID 16115130, PMID 16158312, PMID 16275934, PMID 16540422, PMID 16670265, PMID 16709929, PMID 16775235, PMID 16882711, PMID 16990776, PMID 17021321
P30CA015704 (28), P30CA006973 (14), P01CA018029 (12), P30CA043703 (10), 2016 (9), U01CA070095 (9), U10CA031946 (9), 2017 (7), P01CA078902 (7), U10CA032102 (7), 2015 (6), 2018 (6), P30CA016672 (6), 2008 (5), 2014 (5)